Peptide Therapeutics Market by Drug Category (Branded and Generic), Routes of Administration (oral and Parenteral), Therapeutic Application (Acromegaly; Cancer – Zoladex, Velcade, Lupron/ Enantone/ Eligard; Cardiovascular – Angiomax, Integrilin; Central Nervous System – Copaxone; Gastrointestinal Disorders – Gattex, Linzess; Hematological Disorders – Firazyr, Kalbitor; Infection –Incivek, Victrelis; Metabolic Disorders – Victoza, -etta; and Respiratory Disorders) and Forecast 2017-2021

Peptide Therapeutics Market by Drug Category (Branded and Generic), Routes of Administration (oral and Parenteral), Therapeutic Application (Acromegaly; Cancer – Zoladex, Velcade, Lupron/ Enantone/ Eligard; Cardiovascular – Angiomax, Integrilin; Central Nervous System – Copaxone; Gastrointestinal Disorders – Gattex, Linzess; Hematological Disorders – Firazyr, Kalbitor; Infection –Incivek, Victrelis; Metabolic Disorders – Victoza, -etta; and Respiratory Disorders) and Forecast 2017-2021

Peptide drugs offer certain advantages as drugs due to their high biological activity, high specificity and low toxicity. Currently, most peptide drugs are administered by the parental route and approximately 75% are given as injectables. However, alternative administration forms are gaining increasing traction, including oral, intranasal, and transdermal delivery routes. The United States (US) and European Union (EU) are the major markets for drugs of all kinds and, as a consequence, first approvals for peptide therapeutics have occurred primarily in one of these two regions. The near-term prospects for additional approvals are excellent because the pipeline includes more than a dozen molecules in late-stage clinical studies and marketing approval applications. Recent successes in the development of peptides as therapeutics are likely to spur additional growth in this sector.

The global peptide therapeutics market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug category (branded and generic), routes of administration (oral and parenteral), therapeutic application (Acromegaly; Cancer – Zoladex, Velcade, Lupron/ Enantone/ Eligard; Cardiovascular – Angiomax, Integrilin; Central Nervous System – Copaxone; Gastrointestinal Disorders – Gattex, Linzess; Hematological Disorders – Firazyr, Kalbitor; Infection –Incivek, Victrelis; Metabolic Disorders – Victoza, Byetta; and Respiratory Disorders), and also forecasts growth trends (CAGR% – 2017 to 2021).

The global peptide therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global peptide therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global peptide therapeutics market and included in this report are Amgen, Inc., AstraZeneca plc., Bachem Holding AG, CordenPharma International GmbH, Eli Lilly and Company, Ipsen S.A., Lonza Group Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Ltd., and Teva Pharmaceutical Industries Ltd.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Peptide Therapeutics Market

1. Drug Category
1.1. Branded
1.2. Generic

2. Route of Administration
2.1. Oral
2.2. Parenteral

3. Application
3.1. Acromegaly
3.2. Cancer
3.2.1. Zoladex (goserelin)
3.2.2. Velcade (bortezomib)
3.2.3. Lupron/ Enantone/ Eligard (leuprorelin)
3.2.4. Others
3.3. Cardiovascular
3.3.1. Angiomax (bivalirudin)
3.3.2. Integrilin (eptifibatide)
3.3.3. Central Nervous System
3.3.4. Copaxone (glatiramer)
3.4. Gastrointestinal Disorders
3.4.1. Gattex (teduglutide)
3.4.2. Linzess (linaclotide)
3.5. Hematological Disorders
3.5.1. Firazyr (icatibant)
3.5.2. Kalbitor (ecallantide)
3.6. Infection
3.6.1. Incivek (telaprevir)
3.6.2. Victrelis (boceprevir)
3.7. Metabolic Disorders
3.7.1. Victoza (liraglutide)
3.7.2. Byetta (exenatide)
3.7.3. Others
3.8. Respiratory Disorders
3.9. Others

4. Company Profiles
4.1. Amgen, Inc.
4.2. AstraZeneca plc.
4.3. Bachem Holding AG
4.4. CordenPharma International GmbH
4.5. Eli Lilly and Company
4.6. Ipsen S.A.
4.7. Lonza Group Ltd.
4.8. Merck & Co., Inc.
4.9. Novartis AG
4.10. Novo Nordisk A/S
4.11. PolyPeptide Group
4.12. Roche Holdings AG
4.13. Sanofi
4.14. Takeda Pharmaceutical Company Ltd.
4.15. Teva Pharmaceutical Industries Ltd.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*